In its latest financial report, Monte Rosa Therapeutics has announced a significant partnership with Novartis, alongside progress in its pipeline of drug candidates. The partnership involves a global ...

Mapping cell types in MS lesions reveals unique tissue niches and interactions, offering insights into the molecular drivers of multiple sclerosis progression.

The FDA has approved an antibiotic called minocycline for the treatment of rosacea in adults. The drug, which is taken orally ...

Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader, more comprehensive approach to diagnosis ...

operating a drug factory and failure to maintain the proper lane. He is being held on a $250,000 bond and is scheduled to appear in Norwich Superior Court on Nov. 5. Police said additional charges ...

Seaport Therapeutics (“Seaport or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

Ianalumab (previously known as VAY736) is a novel BAFF-targeting antibody that was recently evaluated in patients with pSS.

Novartis reports strong Q3 earnings but faces investor concerns over revenue adjustment and pipeline uncertainties. Learn more about NVS stock here.

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the third quarter of 2024. Core earnings ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...